BIVI ▲ +10.4% - BioVie Inc. $BIVI - BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid BioVie shares rose 10.4% after the company announced it will host a conference call to discuss topline data from its Phase 2 ADDRESS-LC trial evaluating bezisterim as a treatment for Long Covid. The announcement of clinical trial results, particularly for an emerging indication like Long Covid, typically drives investor interest in biotech stocks. 14-SEP-2026 04:01 PM ET